Inactivation and Inducible Oncogenic Mutation of p53 in Gene Targeted Pigs

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Leuchs, Simon ^a   Saalfrank, Anja ^a   Merkl, Claudia ^a   Flisikowska, Tatiana ^a   Edlinger, Marlene ^a   Durkovic, Marina ^a   Rezaei, Nousin ^a   Kurome, Mayuko ^b   Zakhartchenko, Valeri ^b   Kessler, Barbara ^b   Flisikowski, Krzysztof ^a   Kind, Alexander ^a   Wolf, Eckhard ^b   Schnieke, Angelika ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE ACTIVATION; GENE INACTIVATION; GENE MUTATION; GENE TARGETING; GENETIC RECOMBINATION; HETEROZYGOSITY; HOMOZYGOSITY; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PIGLET; SOMATIC MUTATION; TP53 GENE;

ANIMALS; CLONE CELLS; GENE TARGETING; GENES, P53; INTEGRASES; MESENCHYMAL STROMAL CELLS; MODELS, ANIMAL; SWINE; TRANSFECTION;

ANIMALIA; MAMMALIA; PYRONIA TITHONUS; RODENTIA; SUIDAE; SUS;

EID: 84867171118     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043323     Document Type: Article

References (33)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al., editors. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. Based on November 2011 SEER data submission, posted to the SEER web site, April 2012. Available: http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed 2012 Feb 2.
2. Levine AJ, Oren M, (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9: 749-758.
3. Malkin D, (2011) Li-fraumeni syndrome. Genes Cancer 2: 475-484.
4. Olivier M, Hollstein M, Hainaut P, (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2: a001008.
5. Oren M, Rotter V, (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2: a001107.
6. Willis A, Jung EJ, Wakefield T, Chen X, (2004) Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23: 2330-2338.
7. Khromova NV, Kopnin PB, Stepanova EV, Agapova LS, Kopnin BP, (2009) p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett 276: 143-151.
8. Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, et al. (2011) Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 18: 271-281.
9. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
10. Donehower LA, Lozano G, (2009) 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9: 831-841.
11. Prather RS, Sutovsky P, Green JA, (2004) Nuclear remodeling and reprogramming in transgenic pig production. Exp Biol Med (Maywood) 229: 1120-1126.
12. Hong IH, Jeong YW, Shin T, Hyun SH, Park JK, et al. (2011) Morphological abnormalities, impaired fetal development and decrease in myostatin expression following somatic cell nuclear transfer in dogs. Mol Reprod Dev 78: 337-346.
13. Michael D, Oren M, (2003) The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13: 49-58.
14. Midgley CA, Lane DP, (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189.
15. Qiu Y, Shen Y, Li X, Liu Q, Ma Z, (2008) Polyclonal antibody to porcine p53 protein: a new tool for studying the p53 pathway in a porcine model. Biochem Biophys Res Commun 377: 151-155.
16. Rubio R, Garcia-Castro J, Gutierrez-Aranda I, Paramio J, Santos M, et al. (2010) Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 70: 4185-4194.
17. Dunkern TR, Wedemeyer I, Baumgartner M, Fritz G, Kaina B, (2003) Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair (Amst) 2: 49-60.
18. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, et al. (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3: 387-402.
19. Aigner B, Renner S, Kessler B, Klymiuk N, Kurome M, et al. (2010) Transgenic pigs as models for translational biomedical research. J Mol Med (Berl) 88: 653-664.
20. Kuzmuk KN, Schook LB (2011) Pigs as a Model for Biomedical Sciences. In: Rothschild MF, and Ruvinsky A, editors. The Genetics of the Pig. 2nd ed: CABI Publishing. pp. 426-444.
21. Lane DP, Cheok CF, Lain S, (2010) p53-based cancer therapy. Cold Spring Harb Perspect Biol 2: a001222 Epub 2010 May 12.
22. Donehower LA, (1996) The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol 7: 269-278.
23. van Boxtel R, Kuiper RV, Toonen PW, van Heesch S, Hermsen R, et al. (2011) Homozygous and heterozygous p53 knockout rats develop metastasizing sarcomas with high frequency. Am J Pathol 179: 1616-1622.
24. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
25. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, et al. (1998) Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17: 1061-1068.
26. Goh AM, Coffill CR, Lane DP, (2011) The role of mutant p53 in human cancer. J Pathol 223: 116-126.
27. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483.
28. Frese KK, Tuveson DA, (2007) Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658.
29. Flisikowska T, Merkl C, Landmann T, Eser S, Rezaei N, et al. (2012) A porcine model of familial adenomatous polyposis. Gastroenterology (in press).
30. Klymiuk N, Bocker W, Schonitzer V, Bahr A, Radic T, et al. (2012) First inducible transgene expression in porcine large animal models. FASEB J 26: 1086-1099.
31. Peitz M, Pfannkuche K, Rajewsky K, Edenhofer F, (2002) Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes. Proc Natl Acad Sci U S A 99: 4489-4494.
32. Munst B, Patsch C, Edenhofer F, (2009) Engineering cell-permeable protein. J Vis Exp doi: 10.3791/1627.
33. Merkl C, Leuchs S, Saalfrank A, Kind A, Schnieke A, (2011) RNA interference in pigs: comparison of RNAi test systems and expression vectors. Mol Biotechnol 48: 38-48.